Please login to the form below

Not currently logged in
Email:
Password:

FDA approval for OTC delayed release omeprazole in US

The FDA grants final approval to Perrigo and its partner Dexcel Pharma Technologies to sell 20 mg omeprazole delayed-release tablets in the US

Over-the-counter (OTC) drug manufacturer and marketer Perrigo has said that the FDA has granted final approval to its partner Dexcel Pharma Technologies to sell 20 mg omeprazole delayed-release tablets in the US.

As the exclusive marketer and distributor of this product for the store brand OTC market in the US, Perrigo expects to begin shipping its product during Q1 2008. The company says its full year annual sales could be in the region of USD 150m to USD 200m.

Omeprazole is the active ingredient in UK-headquartered AstraZeneca's now off-patent antacid blockbuster Prilosec. Prilosec OTC is indicated for the treatment of frequent heartburn and had estimated current annual sales of approximately USD 750m in all US outlets, says Perrigo.

Based on pre-launch estimates, Perrigo's Omeprazole product is expected to contribute between USD 0.20 and USD 0.25 earnings per share in FY08. As a result of the Omeprazole launch, FY08 earnings are expected to be in the range of USD 1.32 to USD 1.47 per share.

Omeprazole is also sold OTC in a non-delayed release form by Proctor & Gamble.

11th December 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oxford University Press

Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...

Latest intelligence

COVID-19 is redefining the value of ‘critical jobs’: An opportunity for social care?
...
How to keep your weight under control during lockdown
...
Brands stepping up to show solidarity during COVID-19
The brands that are stepping up to show solidarity during COVID-19 will be those that are remembered long after pandemic passes....

Infographics